Tango Therapeutics, Inc. (TNGX) Net earnings per share growth forecast for next year
Geopolitical conflicts are hindering international drug trials and complicating the delivery of biomaterials. The projected EPS growth for the next fiscal year confirms the impact of these factors, where -22.10 represents the current level of the metric. A reliance on synthetic lethality and diversified targets, combined with streamlined, verified component logistics, creates a solid foundation for the future earnings of Tango Therapeutics (TNGX).
Metric breakdowns and analytics for Tango Pharma (TNGX)
- price and consensus price forecast:
- market capitalization details:
- company book value details:
- company liabilities and liquidity data:
Debt to Equity Tango Therapeutics|TNGX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Tango Therapeutics Inc|TNGX - Company Total Indebtedness|Debt to Book Value Tango Therapeutics|TNGX - Amount of Long-Term Liabilities|Company Short-Term Debts Tango Therapeutics|Quick Ratio tangotx.com
- earnings and market ratios statistics:
TNGX - Company Net Income|Expected Profit Tango Therapeutics|TNGX - Company Value to Net Income|Forward P/E Multiple tangotx.com|TNGX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tango Therapeutics, Inc.|TNGX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Tango Therapeutics|TNGX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months tangotx.com|TNGX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Tango Therapeutics
- revenue and sales proceeds data:
Analysis of all company metrics:Tango Pharma
This indicator captures the daily dynamics of net profit forecast revisions, signaling a fundamental trend reversal through the narrowing volatility of analyst estimates. Monitoring the expected change in net profit is critical for stress-testing the Tango Therapeutics (TNGX) portfolio, as the company relies on external financing rather than operating revenue prior to FDA approval and the acquisition of pricing power.
Direct competitors
Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics Inc (JANX)|Expected earnings per share growth for next year Arcus Bio RCUS|Zymeworks Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Iovance Corp IOVA|IMTX - Net earnings per share growth forecast for next year|XNCR (xencor.com) - Projected earnings per share growth rate for next year|Compass Therapeutics Corp (CMPX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Replimune Corp (REPL)|Expected earnings per share growth for next year LYEL|IPHA - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year PYXS (Pyxis Oncology, Inc.)|Projected earnings per share increase next year CGEN|Earnings growth forecast for next year IOBT (IO Biotech)|Expected earnings per share trend next year STRO|minktherapeutics.com - Earnings growth forecast for next year|Expected net earnings per share growth next year Werewolf Therapeutics, Inc.|Immix (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cue Biopharma|Earnings growth forecast for next year pdsbiotech.com|Net earnings per share growth forecast for next year sonnetbio.com (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Inc. - Expected earnings per share growth for next year|LAVA Therapeutics N.V. (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|LPTX: Net earnings per share growth forecast for next year|Intensity Therapeutics (INTS) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Sensei Bio (SNSE)|TOVX (Theriva Biologics Inc) - Earnings growth forecast for next year|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year
